Better endurance and faster recovery from hard training are the best-established effects, drawn mainly from whole-root extract rather than the isolated compound. Mood steadiness under stress is plausible but unsettled. Lifespan, brain, liver and cancer claims rest on animals. Safety is reassuring at studied doses, with no data beyond three months. A low-cost, short-horizon experiment. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 70–85 mg/dL | Detects additive glucose lowering, the main metabolic risk |
| Fasting insulin | 2–5 µIU/mL | Tracks the insulin-sensitivity claim directly |
| Glycated hemoglobin | 4.8–5.4% | Confirms that any glucose shift is sustained, not a one-off reading |
| Alanine and aspartate aminotransferase | 10–26 U/L (women), 10–30 U/L (men) | Liver safety, and the organ where the fatty-liver claim would show |
| High-sensitivity C-reactive protein | < 0.5 mg/L | The inflammation mechanism claimed for the compound |
| Estimated glomerular filtration rate | > 90 mL/min/1.73 m² | Clearance route for the compound; falling values raise exposure |
| Heart-rate variability | No established salidroside target; track change from the individual's own 7-day baseline | Objective proxy for stress-axis load and recovery |
| Morning cortisol | 10–15 µg/dL | The stress-hormone axis the compound is claimed to modulate |
Cadence: Baseline before starting; glucose and insulin rechecked at 4 weeks, the full panel at 12 weeks, then every 6–12 months on continued use. Daily fasting-glucose self-checks for the first 2 weeks apply to anyone taking glucose-lowering medication.